BA/F3_TFG-NTRK1激酶Kinase穩(wěn)定表達(dá)細(xì)胞株-BioVector NTCC保藏中心
I. Introduction
Cell Line Name：

BA/F3_TFG-NTRK1

Gene Synonyms:

TRK-fused gene ,HMSNP, SPG57, TF6, TRKT3;neurotrophic receptor tyrosine kinase 1 ,MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA

Host Cell:

Ba/F3

Stability: 16 passages
Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS+1 ug/ml puromycin

Mycoplasma Status:

Negative


II.Background
NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013).

a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013).

b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013).

c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013)


III. Representative Data
1. Anti-proliferation assay



Figure 1. Anti-proliferation assay of two reference compounds on the BA/F3_TFG-NTRK1 Stable Cell Line


IV. Thawing

Thawing: Protocol
1. Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
2. Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
3. Pellet cells by centrifugation at 200 x g force for 5 min, and discard the medium.
4. Resuspend the cells in complete growth medium.
5. Add 10 ml of the cell suspension in a 10 cm dish.
6. Add promycin to a concentration of 1 μg/ml the following day.
Kinase細(xì)胞株



現(xiàn)代新藥研發(fā)的關(guān)鍵首先是尋找，確定和制備藥物作用靶點(diǎn)。在500多個(gè)已發(fā)現(xiàn)的藥物靶點(diǎn)里中，GPCR，Ion Channel，Kinase使用的最為廣泛。




激酶(kinase)是一類從高能供體分子（如ATP）轉(zhuǎn)移磷酸基團(tuán)到特定靶分子（底物）的酶；這一過程謂之磷酸化。許多腫瘤的發(fā)生是由某些與生長(zhǎng)相關(guān)的“激酶”發(fā)生突變導(dǎo)致異?；罨鸬模蚨槍?duì)這些突變激酶的抑制劑能夠有效抑制這些激酶的活性，從而達(dá)到抑制癌細(xì)胞增長(zhǎng)的目的。
BioVector NTCC質(zhì)粒載體菌種細(xì)胞蛋白抗體基因保藏中心

電話：+86-010-53513060

網(wǎng)址：www.nedfriskphoto.com